Skip to main content

Table 1 Patient characteristics at baseline

From: Pharmacist involvement in the inhaler choice improves lung function in patients with COPD: a prospective single-arm study

Variable n = 36
Age, years 71.7 ± 9.1
Male sex, n (%) 31 (86.1)
ECOG performance status, n (%)
 0 29 (80.6)
 1 4 (11.1)
 2 1 (2.8)
 3 2 (5.6)
Body weight, kg 62.0 ± 10.9
Body surface area, m2 1.68 ± 0.17
FEV1, L 1.60 ± 0.54
Percentage of predicted FEV1 (%) 59.69 ± 16.35
COPD stage, n (%)*
 Stage I 4 (11.1)
 Stage II 21 (58.3)
 Stage III 10 (27.8)
 Stage IV 1 (2.8)
GOLD 2017 category, n (%)
 Group A 6 (16.7)
 Group B 19 (52.8)
 Group C 1 (2.8)
 Group D 10 (27.7)
Smoking status, n (%)
 Smoking history, pack-years 53.5 ± 27.36
 Never / former / current smoker 0 / 32 / 4
Prior history of exacerbation within 1 year, n (%)
 0 exacerbations 36 (100)
 1 exacerbation 0
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group performance status, FEV1 forced expiratory volume in 1 s. Data are presented as mean ± SD. *COPD stage (based on post-bronchodilator FEV1) is as follows: Stage I indicates FEV1 ≥ 80% predicted; Stage II, 50% ≤ FEV1 < 80% predicted; Stage III, 30% ≤ FEV1 < 50% predicted; and Stage IV, FEV1 < 30% predicted